RDX-002

· Response Pharmaceuticals

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for RDX-002, covering 2025-12-23 to 2026-07-02. Get the full timeline:

Most recent: Clinical Trial Results: Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists [Phase 2]